共 21 条
[1]
Ponce Lorenzo J.(2007)Carcinoma of unknown primary site: development in a single institution of a prognostic model based on clinical and serum variables Clin Trans Oncol 9 452-458
[2]
Segura Huerta A.(2004)Prognostic and predictive factors of patients with cancer of unknown origin treated with a paclitaxel-based chemotherapy Med Clin (Barc) 122 216-218
[3]
Díaz Beveridge R.(1997)Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide J Clin Oncol 15 2385-2393
[4]
Muñoz A.(2002)Development of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site J Clin Oncol 20 4679-4683
[5]
Fuente N.(2002)Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients Ann Oncol 13 308-317
[6]
Barceló R.(2004)Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335-2342
[7]
Hainsworth J.D.(2006)Bevacizumab improves outcomes of patients with metastatic colorectal cancer (mCRC) treated with IFL with or without bevacizumab (BV) independent of baseline risk J Clin Oncol 24 155s-undefined
[8]
Erland J.B.(undefined)undefined undefined undefined undefined-undefined
[9]
Kalman L.A.(undefined)undefined undefined undefined undefined-undefined
[10]
Culine S.(undefined)undefined undefined undefined undefined-undefined